PRIM2 Promotes Cell Cycle and Tumor Progression in p53-Mutant Lung Cancer
Open Access
Abstract
P53 is a common tumor suppressor, and its mutation drives tumorigenesis. What is more, p53 mutations have also been reported to be indicative of poor prognosis in lung cancer, but the detailed mechanism has not been elucidated. In this study, we found that DNA primase subunit 2 (PRIM2) had a high expression level and associated with poor prognosis in lung cancer. Furthermore, we found that PRIM2 expression was abnormally increased in lung cancer cells with p53 mutation or altered the p53/RB pathway based on database. We also verified that PRIM2 expression was elevated by mutation or deletion of p53 in lung cancer cell lines. Lastly, silence p53 increased the expression of RPIM2. Thus, these data suggest that PRIM2 is a cancer-promoting factor which is regulated by the p53/RB pathway. The p53 tumor-suppressor gene integrates numerous signals that control cell proliferation, cell cycle, and cell death; and the p53/RB pathway determines the cellular localization of transcription factor E2F, which regulates the expression of downstream targets. Next, we explored the role of PRIM2 in lung cancer and found that knockdown of PRIM2 induced cell cycle arrest, increased DNA damage, and increased cell senescence, leading to decreased lung cancer cell proliferation. Lastly, the positive correlation between PRIM2 and E2F/CDK also indicated that PRIM2 was involved in promoting cell cycle mediated by p53/RB pathway. These results confirmed that the expression of PRIM2 is regulated by the p53/RB pathway in lung cancer cells, promotes DNA replication and mismatch repair, and activates the cell cycle. Overall, we found that frequent p53 mutations increased PRIM2 expression, activated the cell cycle, and promoted lung cancer progression.Keywords
Funding Information
- National Natural Science Foundation of China (81973356, 21JCZDJC00060, 3206054, 91923101, 63213082, 92122017)
- Natural Science Foundation of Tianjin Municipality (81973356, 21JCZDJC00060, 3206054, 91923101, 63213082, 92122017)
- Fundamental Research Funds for the Central Universities of Nankai University (81973356, 21JCZDJC00060, 3206054, 91923101, 63213082, 92122017)
This publication has 31 references indexed in Scilit:
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerNature Communications, 2015
- TSPAN2 Is Involved in Cell Invasion and Motility during Lung Cancer ProgressionCell Reports, 2014
- Molecular sputum analysis for the diagnosis of lung cancerBritish Journal of Cancer, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- TP53 Mutations in Nonsmall Cell Lung CancerBioMed Research International, 2011
- Identification of a Novel Biomarker, SEMA5A, for Non–Small Cell Lung Carcinoma in Nonsmoking WomenCancer Epidemiology, Biomarkers & Prevention, 2010
- The role of p53 in treatment responses of lung cancerBiochemical and Biophysical Research Communications, 2005
- RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancerOncogene, 2002
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002